Servier Archives -

News/ News/ News/ Oncology/ R&D

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Phil Taylor chemotherapy, Ipsen, Oncology, Onivyde, Servier, small cell lung cancer 0 Comment

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/

News/ News/ News/ Oncology/ Sales and Marketing

FDA clears new first-line use for Servier’s Tibsovo in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business

FDA clears new first-line use for Servier’s Tibsovo in AML

https://pharmaphorum.com/news/fda-clears-new-first-line-use-for-serviers-tibsovo-in-aml/

News/ News/ UK & Europe

Judge shuts down Servier’s argument that NHS should have stopped prescribing its drugs

Jonah Comstock ACE inhibitors, drug prices, generics, perindopril, Servier 0 Comment

A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive

Judge shuts down Servier’s argument that NHS should have stopped prescribing its drugs

https://pharmaphorum.com/news/judge-shuts-down-serviers-argument-that-nhs-should-have-stopped-prescribing-its-drugs/

News/ News/ Oncology

ASH: Servier’s Tibsovo poised for first-line used in AML

Phil Taylor acute myeloid leukaemia, Oncology, Servier, targeted oncology, Tibsovo 0 Comment

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for

ASH: Servier’s Tibsovo poised for first-line used in AML

https://pharmaphorum.com/news/ash-serviers-tibsovo-poised-for-first-line-used-in-aml/

News/ News/ R&D

Server cans autism hope bumetanide after phase 3 fails

Phil Taylor autism, autism spectrum disorder, neurology, Servier 0 Comment

Servier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to

Server cans autism hope bumetanide after phase 3 fails

https://pharmaphorum.com/news/server-cans-autism-hope-bumetanide-after-phase-3-fails/

News/ News/ Oncology

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

Phil Taylor acute myeloid leukaemia, Agios, haemotology, Oncology, Servier, targeted oncology 0 Comment

Just three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

https://pharmaphorum.com/news/servier-gets-a-win-for-cancer-drug-tibsovo-bought-in-1-8bn-agios-deal/

Market Access/ News/ News

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

Phil Taylor AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier 0 Comment

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

https://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/

News/ News/ Oncology

Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn

Phil Taylor Agios, M&A, Oncology, Servier 0 Comment

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise

Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn

https://pharmaphorum.com/news/servier-cancer-agios-oncology/

News/ News/ R&D

Amgen shares down as heart failure drug disappoints in phase 3 trial

Richard Staines Amgen, Bayer, cardiology, Cytokinetics, heart failure, Merck & Co, Servier 0 Comment

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug

Amgen shares down as heart failure drug disappoints in phase 3 trial

https://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/

Trending

Servier

Login